Fear and misinformation keep hundreds of thousands of eligible patients from considering clinical trials every year. Some myths are decades old, passed down from a time when research ethics were genuinely weaker. Others are just misunderstandings that no one has clearly corrected. All of them have real consequences — for patients who need access to new treatments and for the research that would benefit everyone.
Here are the ten most common myths, and what's actually true.
About this article: Educational and informational only. Does not constitute medical advice. Whether a specific trial is appropriate for you depends on your individual situation — always discuss with your physician.
The truth
Placebos are used far less often than most people assume, and rarely alone. In most trials for serious conditions, the control arm receives current standard-of-care treatment — not a sugar pill. Placebo-only arms are ethically permissible only when no proven treatment exists for the condition being studied. Even when a placebo arm exists, you are always told before you enroll (this is a requirement of informed consent), and trials must have stopping rules that protect participants if the placebo arm is clearly underperforming.
Ask the research coordinator exactly what the control arm receives. In most Phase 3 trials, it's the current best available therapy.
The truth
This is one of the most damaging myths in medicine. In reality, many trials are designed specifically for patients who have not yet tried a particular treatment — because the researchers want to see how the drug performs in treatment-naive patients. Others recruit people in remission, people with early-stage disease, or even healthy volunteers.
Many oncologists now recommend exploring trials before exhausting standard treatments, not after. The earlier in the treatment journey, the more options often exist.
The truth
Clinical trials carry risk — that's true. But every trial must be approved by an independent Institutional Review Board (IRB) before enrolling anyone. Larger trials have a Data Safety Monitoring Board that reviews safety data in real time and can stop the trial if harm is emerging. Serious adverse events must be reported to the FDA within days.
The risk level varies enormously by phase and trial type. Phase 3 trials — which most patients encounter — have extensive prior safety data behind them from Phase 1 and 2 studies. The oversight system is significantly more rigorous than it was two or three decades ago.
The truth
Modern clinical research is built on the concept of informed consent. Before you agree to participate in anything, you must receive a full written description of the study: what will happen, what the known risks are, what your alternatives are, and what you will be compensated. You have the right to take time to decide, to ask questions, to bring an advocate, and to withdraw at any time without penalty. You are a voluntary participant — not a subject.
The “guinea pig” framing comes from historical abuses like Tuskegee — real events that happened before modern informed consent requirements. Those protections exist precisely because of what went wrong. The current framework is fundamentally different.
The truth
Studies consistently show that most physicians do not proactively discuss clinical trials with eligible patients — not because they're withholding information, but because they don't have time to track the trial landscape across dozens of conditions. With over 50,000 recruiting trials in the U.S. alone, no physician can be fluent in all of them.
It's entirely reasonable — and increasingly common — for patients to research trials themselves and bring specific NCT numbers to their physicians for discussion. Physicians can help evaluate fit, but you can initiate the conversation.
The truth
Large Phase 3 trials routinely run at hundreds of sites across the country, including community hospitals, private practices, and outpatient clinics — not just academic medical centers. Additionally, the rise of decentralized clinical trials (DCTs) means many studies now allow remote participation via telemedicine, home nursing visits, and mail-order study medications, eliminating the need for in-person visits to a research center entirely.
When searching, expand your radius. And specifically look for trials labeled “decentralized” or those that list home visits as an option.
The truth
Participation in any clinical trial is entirely voluntary and can be ended at any time. Federal regulation (and the Belmont Report principles underlying it) specifically prohibits coercion or undue influence in clinical research. You cannot be threatened, penalized, or denied your regular medical care for withdrawing from a trial.
There may be a request for a safety follow-up visit after withdrawal — to monitor any lingering effects of the study drug — but you have the right to decline even that.
The truth
The Affordable Care Act requires most insurers to cover routine care costsin qualifying clinical trials — things like office visits, standard lab tests, scans, and hospitalizations that would be covered under normal care. The experimental drug and research-specific procedures are typically covered by the trial sponsor. This means your out-of-pocket exposure for trial participation is often similar to or less than standard care.
Medicare and Medicaid have their own coverage rules for trials. State laws add additional protections in many states. Ask both your insurer and the research coordinator specifically what will be billed to insurance and what the sponsor covers.
The truth
While oncology generates the most trial activity, over 50,000 recruiting trials in the U.S. cover virtually every area of medicine: autoimmune diseases, neurological conditions, cardiovascular disease, metabolic disorders, mental health conditions, infectious diseases, rare diseases, and more. Some of the most active trial landscapes right now are in type 2 diabetes (GLP-1 combinations), rheumatoid arthritis (bispecific antibodies), Alzheimer's disease, and obesity. If you have any chronic condition, there are likely trials actively recruiting for it right now.
The truth
Most trial sponsors provide medical care at no cost for injuries or complications directly caused by the study drug or procedures. The informed consent form is required to explain what the sponsor will cover. You should read this section carefully and ask explicitly before you sign.
It's also worth noting that participants in clinical trials are among the most closely monitored patients in medicine. You receive more frequent lab work, more imaging, more check-ins with clinicians than you typically would under standard care. Problems are more likely to be caught early — not ignored.
The pattern behind the myths
Most of these myths have the same root: they describe clinical research as it existed before modern oversight systems were built. The Tuskegee study ended in 1972. The Belmont Report that overhauled research ethics was published in 1979. IRB requirements have been continuously strengthened since. The system today — with mandatory IRB review, informed consent requirements, DSMB safety monitoring, and FDA reporting obligations — is structurally different from the era that generated these fears. The fears haven't updated to match the system.
See what trials are recruiting for your condition
Search live ClinicalTrials.gov data. Tidera explains each trial in plain English, shows fit scores, and generates the questions worth asking — for free.
Search Trials Now →Frequently Asked Questions
If the myths aren't true, why do they persist?
Partly because of legitimate historical abuses that were real and devastating. Partly because media coverage of clinical trials focuses on rare catastrophic outcomes rather than the far more common experience of uneventful participation. And partly because no one has been systematically correcting them — until patients start asking questions and getting accurate answers.
Are there still legitimate concerns about clinical trials?
Yes. Phase 1 trials do carry higher uncertainty. Rare but serious adverse events do occur. Not every trial is designed with equal rigor. The goal of this article isn't to tell you there's nothing to consider — it's to replace myths with accurate concerns, so you can ask the right questions and make a genuinely informed decision.
Who should consider a clinical trial?
Anyone with a serious or chronic condition who wants to understand all their options. This includes people who are currently doing well on treatment (many trials seek exactly that patient profile), people who have not yet started any treatment, and people who want access to therapies not yet commercially available.